Intraclass biologic switching had better short-term efficacy in psoriasis, but both intraclass and interclass switching were effective long-term.

The recurrence rates of curettage alone are comparable to that of curettage with electrodessication in patients with keratinocyte carcinoma.

The loved ones of those with cancer report an emotional burden, including concerns about life expectancy, course of treatment, and pain.

A broad spectrum of systemic inflammatory manifestations defines VEXAS syndrome, with cutaneous, respiratory, and vascular involvement commonly reported.

The FDA has appointed George Francis Tidmarsh, MD, PhD, to be the director of the Center for Drug Evaluation and Research.

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

The FDA has issued a CRL to Replimmune regarding the BLA for vusolimogene oderparepvec (RP1) in combination with nivolumab for advanced melanoma.

The prevalence of frailty was 33% among a US-wide cohort of patients with RMDs, with the highest rates found among those with fibromyalgia or CTDs.

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

The HHS is directing the Organ Procurement and Transplantation Network to implement new safety measures following accusations of negligence.

Tumor necrosis factor inhibitor use in patients with IMIDs did not increase the risk of de novo heart failure or worsen existing heart failure.

A total of 4 new recommendations are included as part of the American Academy of Dermatology’s atopic dermatitis guideline updates.